EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Neoadjuvant Therapy‐Induced Remodeling in Pancreatic Ductal Adenocarcinoma: Multimodal Spatial Analysis and Prognosis

Xiaofei Zhang iD, Ruoxin Lan, Danting Li, Yongjun Liu, Sonu Kalyan, Momin Iqbal, Nancy Liu, Jerry Zhang, Iman Hanna, Mala Gupta, Chaohui L Zhao, Weiguo Liu und 5 weitere

Cancer Science · 2026

DOI: 10.1111/cas.70320 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2026. Verfasst von Xiaofei Zhang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, New York University Grossman Long Island School of Medicine, Long Island, New York, USA. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NYU Grossman Long Island School of Medicine Department of Pathology Intradepartmental Research Fund, University of Wisconsin - Madison RIDE Cancer Scholarship, UW-Madison Department of Pathology Intradepartmental R&D Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neoadjuvant therapy (NAT) is increasingly used for pancreatic ductal adenocarcinoma (PDAC); yet most patients only achieve partial response. Pathological treatment response grading focuses on assessing residual tumor burden, often overlooking changes in tumor microenvironment (TME). To address this gap, we compared tumor cells and TME of 13 NAT‐naïve and 23 post‐NAT PDACs using integrated spatial pathomics and transcriptomics, with validation in an independent single‐cell spatial dataset. NAT significantly reduced tumor burden (14.7%–6.2%, p = 0.004), but systemic comparison of 13 cytomorphometric features of tumor cells alone did not reliably distinguish between naïve and NAT cases. In contrast, NAT profoundly remodeled TME by increasing cancer‐associated fibroblast (CAF) and CD8 + T cell densities, promoting CD8 + T cell‐tumor cell proximity and fibrosis, reducing tumor‐associated neutrophils, and redistributing tertiary lymphoid structures (TLSs). Spatial transcriptomics shows NAT induced apoptosis, DNA‐damage response, and AGC‐kinase (S_TK_X) signaling in tumor cells, and upregulated complement pathway, p53 signaling, and cellular senescence program in TME. Cross‐platform single‐cell spatial analysis revealed decreased regulatory T cells (Treg) and a shift from myofibroblastic (mCAF) to inflammatory CAF (iCAF). Importantly, post‐NAT patients with more fibrosis had longer overall survival ( p = 0.02), and higher B‐cell density showed a favorable trend ( p = 0.06). Together, these results suggest that beyond tumor debulking, NAT induces a coordinated TME remodeling characterized by fibroblast reprogramming, matrix fibrosis, and immune spatial reorganization. Incorporating assessment of NAT‐induced stromal and immune changes into TRG may improve prognostication and guide more precise therapy in post‐NAT PDAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoadjuvant TherapyCarcinoma, Pancreatic DuctalPancreatic NeoplasmsHumansTumor MicroenvironmentPrognosisFemaleMaleCD8-Positive T-LymphocytesCancer-Associated FibroblastsGene Expression ProfilingGene Expression Regulation, NeoplasticSpatial Transcriptomics

Stichwörter der Autor:innen

neoadjuvant therapy (NAT)pancreatic ductal adenocarcinoma (PDAC)spatial analysisspatial transcriptomicstumor microenvironment (TME)

Autor:innen und Institutionen

  • Department of Pathology, New York University Grossman Long Island School of Medicine, Long Island, New York, USA.
  • Department of Biostatistics and Data Science, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana, USA.
  • Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, Washington, USA.
  • Department of Chemistry, University of Washington School of Medicine, Seattle, Washington, USA.
  • Skyline High School, Sammamish, Washington, USA.
  • Department of Oncology, New York University Grossman Long Island School of Medicine, Long Island, New York, USA.

ORCID-Profile: Xiaofei Zhang

Förderung

  • NYU Grossman Long Island School of Medicine Department of Pathology Intradepartmental Research Fund
  • University of Wisconsin - Madison RIDE Cancer Scholarship
  • UW-Madison Department of Pathology Intradepartmental R&D Fund

Zitieren

APA

Zhang, X., Lan, R., Li, D., Liu, Y., Kalyan, S., Iqbal, M., Liu, N., Zhang, J., Hanna, I., Gupta, M., Zhao, C. L., Liu, W., Melamed, J., Shusterman, M., Widmer, J., Allendorf, J., & Liu, Y. Z. (2026). Neoadjuvant Therapy‐Induced Remodeling in Pancreatic Ductal Adenocarcinoma: Multimodal Spatial Analysis and Prognosis. Cancer Science. https://doi.org/10.1111/cas.70320

Vancouver

Zhang X, Lan R, Li D, Liu Y, Kalyan S, Iqbal M, et al. Neoadjuvant Therapy‐Induced Remodeling in Pancreatic Ductal Adenocarcinoma: Multimodal Spatial Analysis and Prognosis. Cancer Science. 2026. doi:10.1111/cas.70320

BibTeX
@article{Zhang2026,
  author = {Zhang, Xiaofei and Lan, Ruoxin and Li, Danting and Liu, Yongjun and Kalyan, Sonu and Iqbal, Momin and Liu, Nancy and Zhang, Jerry and Hanna, Iman and Gupta, Mala and Zhao, Chaohui L and Liu, Weiguo and Melamed, Jonathan and Shusterman, Michael and Widmer, Jessica and Allendorf, John and Liu, Yao-Zhong},
  title = {Neoadjuvant Therapy‐Induced Remodeling in Pancreatic Ductal Adenocarcinoma: Multimodal Spatial Analysis and Prognosis},
  journal = {Cancer Science},
  year = {2026},
  doi = {10.1111/cas.70320}
}
Kostenlos starten →